Neuromyelitis Optica Spectrum Disorder Market

DelveInsight’s Neuromyelitis Optica Spectrum Disorder Report delivers an in-depth understanding of the Neuromyelitis Optica Spectrum Disorder, historical and forecasted epidemiology, and the Neuromyelitis Optica Spectrum Disorder market trends in the United States EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some Crucial Highlights from the Neuromyelitis Optica Spectrum Disorder Market Report

• According to Orphanet, NMO is found all over the world, with a frequency of 1-2 per 100,000.

• According to Keiko Tanaka et al. (2018)’s report “Prevalence and clinical characteristics of Neuromyelitis Optica Spectrum Disorders in Northern Japan,” the crude prevalence of NMOSD in Northern Japan was 4.1/100,000 (95 percent confidence interval 2.2–6.9), with a slightly higher number of female patients than male patients (female: male 12:2).

• Emerging therapies in the NMOSD market include BAT4406F (Bio-Thera Solutions), CRD1 / cladribine (Chord Therapeutics), Ravulizumab (Alexion Pharmaceuticals), others.

• Key Companies involved in the NMOSD market are Bio-Thera Solutions, Chord Therapeutics, Alexion Pharmaceuticals, among others.

• The increase in the prevalence population of Neuromyelitis Optica Spectrum Disorder patients in the 7MM is the primary driver of market growth.

To know more request sample @ NMOSD Market

The Neuromyelitis Optica Spectrum Disorder market report covers existing clinical practices, new drugs, individual therapies’ market share, and current and forecasted Neuromyelitis Optica Spectrum Disorder market sizes in the 7MM (the United States, the EU5, Germany, Italy, Spain, and France), and Japan.

Neuromyelitis Optica Spectrum Disorder: Disease Overview

Neuromyelitis Optica Spectrum Disorder (NMOSD) also known as Devic disease, is a chronic brain and spinal cord disorder characterised by inflammation of the optic nerve (optic neuritis) and spinal cord inflammation (myelitis).

It was once thought to be a monophasic disease, with episodes of inflammation of one or both optic nerves and the spinal cord lasting only a few days or weeks with no recurrence after the initial episode. Most patients who meet the existing requirements for NMOSD have multiple attacks separated by periods of recovery, according to new research.

Neuromyelitis Optica Spectrum Disorder Epidemiology Segmentation

• Neuromyelitis Optica Spectrum Disorder Total Prevalent Cases

• Neuromyelitis Optica Spectrum Disorder Gender-Specific Prevalence

• Neuromyelitis Optica Spectrum Disorder Age-Specific Prevalence

• Neuromyelitis Optica Spectrum Disorder Diagnosed Cases

• Neuromyelitis Optica Spectrum Disorder NMO-IgG Diagnosed Cases

Neuromyelitis Optica Spectrum Disorder Treatment landscape

The current treatment options for NMOSD are:

• Acute treatment: Methylprednisolone, Corticosteroids

• Preventive treatment: Immunosuppressive Medications, Mycophenolate Mofetil, Azathioprine and Rituximab

• Symptomatic treatment: Anti-Epileptic Medications, Anti-Spasmodics

• Approved therapy: Soliris (eculizumab), Uplinza (inebilizumab-cdon), Enspryng (satralizumab) 

Neuromyelitis Optica Spectrum Disorder Market 

During the forecast period, i.e., 2020–2030, the expected launch of pipeline therapies such as BAT4406F, Ravulizumab, Satralizumab (US and EU), and others will fuel the market’s development.

For more information visit, DelveInsight NMOSD Blog

Neuromyelitis Optica Spectrum Disorder Pipeline Therapies and Key Companies

• BAT4406F: Bio-Thera Solutions

• CRD1 /Cladribine: Chord Therapeutics

• Ravulizumab: Alexion Pharmaceuticals

Table of Contents

Get in touch with our Business executive@ NMOSD Market Insights to know more.

Related Reports

Neuromyelitis Optica Market

DelveInsight’s “Neuromyelitis Optica – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Neuromyelitis Optica , historical and forecasted epidemiology as well as the Neuromyelitis Optica market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/